PILOT STUDY ON BREAST CANCER, CHEMOTHERAPY, AGE AND UFOV

关于乳腺癌、化疗、年龄和 UFOV 的试点研究

• 批准号: 6683744
• 负责人: Carolyn Elizabeth Adams-Price
• 金额: $ 7.03万
• 依托单位: MISSISSIPPI STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6683744
• 关键词: age difference; behavioral /social science research tag; breast neoplasms; clinical research; cognition; cognition disorders; depression; diagnosis design /evaluation; drug adverse effect; female; functional ability; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neuropsychological tests; patient oriented research; transportation /recreation safety; vehicular accident; visual perception; women's health

This RO3 application addresses the NIA (PAR-02-049) objective, "Cancer in the Elderly" (#7) and is relevant to "Basic research in Behavioral Medicine" (#8), "Cognition in Context" (#12), and "Improved Measures and Methods" (#24). The incidence of breast cancer rises dramatically for post-menopausal women and increases with age. Exposure adjusted crash risk rises with age, and scores on cognitive indicators that are highly associated with important daily activities, such as driving, also tend to decline with age. Chemotherapy is a standard treatment for breast cancer and has been associated with poorer performance on neuropsychological tests. However, effects of chemotherapy on cognitive test performance that is most closely associated with everyday functioning, such as driving, have not been examined nor have interactions between age and chemotherapy on cognitive functioning. We will conduct an innovative pilot study to explore whether chemotherapy for breast cancer is associated with impaired performance on a cognitive test that is highly related to performance of important activities, including driving. We will use as a measure the UFOV, a test of visual attention/cognitive processing speed, that correlates highly with IADLs, including driving as well as crash risk. Despite its possible relevance, the UFOV has not been used in chemotherapy studies. This study will focus on three age groups--< 50, 51-69, and 70 and above and will explore age by chemotherapy interactions. The sample will include 35-50 breast cancer survivors who have completed chemotherapy, and 35-50 age-, race-, and education-matched controls. Participants will also be tested on other cognitive tests to compare findings of this study to previous studies. Data on driving behavior, subjective neuropsychological symptoms, depression and positive protective factors will be collected to explore relationships between actual deficits, perceived deficits, protective factors, and driving behavior. Findings of chemotherapy-associated deficits may be important for the safety and independence of breast cancer survivors and may assist in designing interventions. This study will provide critical information for planning a definitive study of effects of chemotherapy and of age/chemotherapy interactions on cognitive functions.

此RO3申请解决了NIA（PAR-02-049）目标，“老年人中的癌症”（＃7），并且与“行为医学的基础研究”（＃8），“上下文中的认知”（＃12）有关和“改进的措施和方法”（＃24）。乳腺癌的发病率急剧上升，而后果妇女随着年龄的增长而增加。暴露调整后的崩溃风险随着年龄的增长而增加，并且在认知指标上的分数与重要的日常活动相关，例如驾驶，也往往随着年龄的增长而下降。化学疗法是乳腺癌的标准治疗方法，与神经心理学测试的性能较差有关。但是，化学疗法对与日常功能最紧密相关的认知测试表现的影响，例如驾驶，尚未检查年龄和化学疗法之间的相互作用，对认知功能。我们将进行一项创新的试点研究，以探讨乳腺癌化学疗法是否与认知测试的表现受损有关，该测试与重要活动的表现高度相关，包括驾驶。我们将用作UFOV的量度，即视觉注意/认知处理速度的测试，与IADL相关，包括驾驶和崩溃风险。尽管可能相关，但UFOV尚未用于化学疗法研究。这项研究将集中于三个年龄组 - <50、51-69和70及以上，并将 通过化学疗法相互作用探索年龄。该样本将包括已完成化学疗法的35-50个乳腺癌幸存者，以及35-50岁的年龄，种族和教育匹配的控制。参与者还将在其他认知测试中进行测试，以将本研究的发现与以前的研究进行比较。将收集有关驾驶行为，主观神经心理症状，抑郁和积极保护因素的数据，以探索实际缺陷，感知的缺陷，保护因素和驾驶行为之间的关系。化学疗法相关缺陷的发现对于安全性和独立性可能很重要 乳腺癌幸存者的生存者，可能有助于设计干预措施。这项研究将提供关键信息，以计划化学疗法和年龄/化学疗法相互作用对认知功能的影响的明确研究。